Skip to main content
Jessica (Sharma) Ailani, MD, Neurology, McLean, VA, MedStar Georgetown University Hospital

Jessica(Sharma)AilaniMDFAHS FAAN

Neurology McLean, VA

Headache

Director, Headache Center Vice Co-Chair Strategic Planning Professor Clinical Neurology Medstar Georgetown University Hospital

Dr. Ailani is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ailani's full profile

Already have an account?

Summary

  • Dr. Jessica Ailani is a neurologist in McLean, VA and is affiliated with MedStar Georgetown University Hospital. She received her medical degree from Stony Brook University School of Medicine and has been in practice 13 years. She specializes in headache and is experienced in headache medicine, migraine disorders, and botulinum toxin injections for headache.

Education & Training

  • NYU School of Medicine
    NYU School of MedicineResidency, Neurology, 2005 - 2008
  • Winthrop-University Hospital
    Winthrop-University HospitalInternship, Internal Medicine, 2004 - 2005
  • Stony Brook University School of Medicine
    Stony Brook University School of MedicineClass of 2004
  • NYU School of Medicine
    NYU School of MedicineResidency, Neurology

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2015 - 2022
  • VA State Medical License
    VA State Medical License 2010 - 2022
  • DC State Medical License
    DC State Medical License 2009 - 2022
  • PA State Medical License
    PA State Medical License 2008 - 2009
  • NY State Medical License
    NY State Medical License 2005 - 2010
  • American Board of Psychiatry and Neurology Neurology
  • UCNSHeadache Medicine

Publications & Presentations

PubMed

Authored Content

  • AHS 2021: Sex and Gender-Specific Differences in HeadacheJune 2021

Press Mentions

  • Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine
    Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of MigraineApril 28th, 2020
  • Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
    Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and IIFebruary 19th, 2020
  • Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
    Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension TrialJanuary 8th, 2020
  • Join now to see all

Hospital Affiliations